Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2022-08-01 Director's Dealing
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice - PM 2 pages 5.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities interests of a director who has ceased to be a director, including the number and class of securities held and relevant interests. This type of document is a report of personal share transactions or holdings by company directors. It is not a financial report, management announcement, or regulatory filing of other types. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on director's interests, confirming this classification with high confidence.
2022-08-01 English
Initial Director's Interest Notice - GM 2 pages 144.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a director and their interests in securities and contracts. This is a report of personal share transactions or interests by a company director, which aligns with the definition of Director's Dealing (DIRS). The document length is short and focused solely on director interests, not a broader financial or management report. Therefore, the correct classification is DIRS.
2022-08-01 English
Nyrada Board Changes 2 pages 206.5KB
Board/Management Information Classification · 100% confidence The document announces changes to the company's board of directors, specifically the appointment of a new Non-Executive Director and the retirement of an existing Non-Executive Director. It focuses on management and board composition updates without presenting financial data, audit information, or other report types. The content aligns with announcements about board or senior management changes rather than financial reports or other filings. Therefore, the document fits the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains detailed information about the board changes, not just a brief announcement or a report publication notice.
2022-08-01 English
Quarterly Activities Report and Appendix 4C 11 pages 446.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and is dated 26 July 2022, covering the quarter ended 30 June 2022. It provides detailed updates on the company's preclinical drug development programs, financial position including cash flow and cash balance, and operational progress. The presence of an Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a brief summary, but a comprehensive report on activities and financials for the quarter. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2022
2022-07-25 English
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis 2 pages 206.1KB
Regulatory Filings Classification · 85% confidence The document is a press release announcing the results of a preclinical study on Nyrada's PCSK9 inhibitor in a novel model of atherosclerosis. It discusses scientific findings, the study's context, and future plans for publication but does not contain financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any formal regulatory filing. The document is an informational announcement about research results intended for investors and the public, typical of an Investor Presentation or general corporate announcement. However, it lacks the detailed financials and strategic content typical of an Investor Presentation (IP). It is more of a corporate news release about scientific progress. Given the options, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2022-07-19 English
Cholesterol-Lowering Program Update 2 pages 216.2KB
Regulatory Filings Classification · 95% confidence The document is a corporate update from Nyrada Inc regarding progress on their Cholesterol-Lowering Program, including delays due to COVID-19, preclinical study timelines, and patent grants. It contains no financial statements, earnings data, or detailed financial analysis. It is an operational update and patent announcement rather than a financial report or regulatory filing. The document is about ongoing research and development progress and patent status, which fits best under a general regulatory announcement category. It is not an earnings release, annual report, or investor presentation. Given the content and length (~5200 characters), it is not a report publication announcement but a regulatory announcement. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.